Plexision currently offers a wide array of lab-developed cell-based diagnostic tests for personalized patient care. The patented technology underlying these testing systems has been used to support custom R&D projects in both the industry and academia.

Plexision’s first product, the FDA-approved Pleximmune^TM blood test predicts transplant rejection. PlexCOVID-19, the most recent blood test, measures the risk and severity of COVID-19 infection.

Our technology can be adapted to -

• Assess disease risk for several immunological disorders.
• Predict the success of a drug for a specific patient.
• Develop dosing recommendations for new immunological drugs.

Rakesh Sindhi

Rakesh Sindhi, M.D., is a transplant surgeon, Co-founder of Plexision, Chief Scientific Officer and Chief Executive Officer, and a member of Plexision’s Board of Directors. He is also Raizman- Haney Chair, Professor of Surgery, Co-Director of Pediatric Transplant Surgery, and Director of the Center for Computational Immunogenetics and Drug Repurposing at the University of Pittsburgh; where he developed all technology underlying Plexision's products. This technology is exclusively licensed to Plexision by the University. Sindhi has authored over 25 patents/applications and has authored or co-author over 130 peer-reviewed papers. He has received several grants from the National Institute of Health allowing him to study the immunogenetic basis of transplant rejection and the genetic basis of biliary atresia, the leading congenital cause of liver transplantation in children.

Ashok Reddy

Ashok Reddy is the Director of Operations and has been with Plexision since 2008. He has worked for over three decades in senior management positions, specializing in all aspects of operations. This experience includes personnel management, contract and labor negotiations, client relationships, operational analysis, budgeting, process re-engineering, and workflow optimization. In the last two decades, Reddy has also held operational roles in the information technology and healthcare IT space. He previously worked as the Senior Vice-President of Operations at Infinite Computer Solutions for over a decade before co-founding IQGateway, a predictive analytics company, where he served as the Chief Operating Officer. Reddy also serves as a consultant to Infinite Healthcare Solutions, a company focused on helping veterans.

Rakesh Sindhi

Rakesh Sindhi, M.D., leads the advisory team. He is a transplant surgeon, Co-founder of Plexision, Chief Scientific Officer and Chief Executive Officer. He is also Raizman-Haney Chair, Professor of Surgery, Co-Director of Pediatric Transplant Surgery, and Director of the Center for Computational Immunogenetics and Drug Repurposing at the University of Pittsburgh; where he developed all technology underlying Plexision's products. This technology is exclusively licensed to Plexision by the University. Sindhi has authored over 25 patents/applications and has authored or co-author over 130 peer-reviewed papers. He has received several grants from the National Institute of Health allowing him to study the immunogenetic basis of transplant rejection and the genetic basis of biliary atresia, the leading congenital cause of liver transplantation in children.

Brandon W. Higgs

Brandon Higgs, PhD, is Advisor to Plexision in the areas of Computational Immunogenetics and AI. He serves as Chief Data Officer for the Diagnostics Platform at Danaher Corporation, where he leads AI and Digital strategy to support development of innovative diagnostics using multimodal data integration, applied machine learning, and scalable digital infrastructure. Previously, Brandon was Vice President, Global Head of Translational Data Science at Genmab, where his team used advanced analytics and AI to support clinical development of precision medicine strategies, including approval of Epkinly® (epcoritamab), where minimal residual disease (MRD) emerged as a key biomarker of long-term outcome. He also established Genmab’s radiomics capability, expanding the company’s use of imaging biomarkers in oncology trials. Previous roles also include leading Translational Bioinformatics at Immunocore in biomarker development for TCR-based bispecific immunotherapies like Kimmtrak®. At AstraZeneca/MedImmune, his translational informatics team developed predictive interferon gene signatures for use of Saphnelo® in lupus, Imfinzi® and Imjudo® in oncology. Brandon’s earlier work includes scientific roles at Gene Logic, SRA Life Sciences, and MITRE, contributing to innovations in toxicogenomics, viral genomics, and biodefense analytics. Brandon holds a BS from Indiana University, an MSc from Johns Hopkins University, and a PhD in Computational Biology and Bioinformatics from George Mason University. He serves as adjunct faculty at Johns Hopkins, where he has developed graduate courses in bioinformatics, and has authored over 100 scientific publications and book chapters.

Kate Lederman

Kate Lederman is Advisor to Plexision in Sales, Marketing and Strategy. She is Senior Sales Executive & Field Sales Trainer, Becton Dickinson (BD) Medical. Kate is a top-performing medical sales leader with a track record of transforming underperforming territories into market leaders in both the start-up and large scale corporate arenas. A three-time President’s Circle winner and BD’s Territory Manager of the Year, Kate delivers not only OR- centric and evidence-based solutions to build strong, trust-based relationships with healthcare professionals. In addition to her role as a field sales leader trainer, Kate brings strategic insight and executional excellence to every initiative. She graduated with high honors from Muhlenberg College where she was a member of the Varsity Basketball and softball teams.